Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process
- PMID: 20393191
- DOI: 10.1152/physrev.00023.2009
Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process
Abstract
Alzheimer disease is characterized by the accumulation of abnormally folded protein fragments, i.e., amyloid beta peptide (Abeta) and tau that precipitate in amyloid plaques and neuronal tangles, respectively. In this review we discuss the complicated proteolytic pathways that are responsible for the generation and clearance of these fragments, and how disturbances in these pathways interact and provide a background for a novel understanding of Alzheimer disease as a multifactorial disorder. Recent insights evolve from the static view that the morphologically defined plaques and tangles are disease driving towards a more dynamic, biochemical view in which the intermediary soluble Abeta oligomers and soluble tau fragments are considered as the main mediators of neurotoxicity. The relevance of proteolytic pathways, centered on the generation and clearance of toxic Abeta, on the cleavage and nucleation of tau, and on the general proteostasis of the neurons, then becomes obvious. Blocking or stimulating these pathways provide, or have the potential to provide, interesting drug targets, which raises the hope that we will be able to provide a cure for this dreadful disorder.
Similar articles
-
Proteases and lipoprotein receptors in Alzheimer's disease.Cell Biochem Biophys. 2004;41(1):139-78. doi: 10.1385/CBB:41:1:139. Cell Biochem Biophys. 2004. PMID: 15371644 Review.
-
Amyloid-beta aggregation.Neurodegener Dis. 2007;4(1):13-27. doi: 10.1159/000100355. Neurodegener Dis. 2007. PMID: 17429215 Review.
-
Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35).Exp Neurol. 2010 Jan;221(1):26-37. doi: 10.1016/j.expneurol.2009.09.005. Epub 2009 Sep 12. Exp Neurol. 2010. PMID: 19751725 Review.
-
Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.Neurobiol Aging. 2005 Oct;26(9):1235-44. doi: 10.1016/j.neurobiolaging.2005.05.022. Neurobiol Aging. 2005. PMID: 16023263 Review.
-
Role of melatonin in Alzheimer-like neurodegeneration.Acta Pharmacol Sin. 2006 Jan;27(1):41-9. doi: 10.1111/j.1745-7254.2006.00260.x. Acta Pharmacol Sin. 2006. PMID: 16364209 Review.
Cited by
-
Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death.Metab Brain Dis. 2020 Jan;35(1):11-30. doi: 10.1007/s11011-019-00516-y. Epub 2019 Dec 6. Metab Brain Dis. 2020. PMID: 31811496 Review.
-
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.J Med Chem. 2011 Apr 14;54(7):2293-306. doi: 10.1021/jm101450p. Epub 2011 Mar 15. J Med Chem. 2011. PMID: 21405086 Free PMC article.
-
RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity.Hum Mol Genet. 2018 Mar 15;27(6):1002-1014. doi: 10.1093/hmg/ddy017. Hum Mol Genet. 2018. PMID: 29329433 Free PMC article.
-
The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases.J Biol Chem. 2016 Feb 26;291(9):4334-41. doi: 10.1074/jbc.R115.704981. Epub 2015 Dec 22. J Biol Chem. 2016. PMID: 26694609 Free PMC article. Review.
-
Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer's Disease.J Neurodegener Dis. 2017;2017:4810232. doi: 10.1155/2017/4810232. Epub 2017 Jan 18. J Neurodegener Dis. 2017. PMID: 28197357 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
